Aditxt subsidiary Ignite Proteomics ends business combination with Copley Acquisition Corp

Aditxt, Inc. reported in an 8-K with an event date of October 9, 2026 that its subsidiary Ignite Proteomics, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Aditxt, Inc., had entered on June 10, 2026 into a Business Combination Agreement with Copley Acquisition Corp, a Cayman Islands exempted company, along with Ignite Proteomics Holdings, Inc., Ignite Merger Sub I Inc., Ignite Merger Sub II LLC, and representatives Jeffrey M. Busch and Chibo Tang.¹

On October 9, 2026, the parties to the Business Combination Agreement entered into a Mutual Termination Agreement, under which Copley and Ignite agreed to terminate the Business Combination Agreement pursuant to Section 8.1(a) thereof, effective immediately.¹

As a consequence, no party retains further rights, remedies, liabilities or obligations under the Business Combination Agreement, except that certain sections and an article survive the termination.¹ In addition, every Ancillary Document tied to the deal, including the Seller Support Agreements, the Insider Letter Amendment, and the Lock-Up Agreements, terminated automatically alongside the main agreement.¹ The termination filing also states that each party will cover its own expenses and that the agreement includes mutual releases of claims related to the original deal, aside from claims arising under the Termination Agreement itself.¹

The filing's cover page lists October 9, 2026 as the date of the earliest event reported, while the document itself was signed on October 15, 2026 by Jeffrey M. Busch, Interim Chief Executive Officer of Aditxt, Inc.¹ The source does not specify when the filing was formally submitted to or accepted by the SEC.